CD274 and cervical adenocarcinoma: Hopefully, from the description of this case, patients with PD-L1 negative, pMMR, non-MSI-H, and TMB-low cervical adenocarcinoma who are incapable of chemotherapy and have particular gene mutations may benefit from immunotherapy.